NANJING, China, July 31, 2023--Nanjing Leads Biolabs Co.，Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") announced today that the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) have approved its first-in-human Investigational New Drug (
| WHO WE ARE
Nanjing Leads Biolabs Co., Ltd is a clinical-stage biotechnology company founded in Nanjing by a team of senior U.S.-trained antibody drug developers.
Since 2014, Our extensive R&D pipeline consist of more than twenty novel tumor immunotherapy molecules based on monoclonal and bispecific antibody technology platforms.
Since 2014, Our extensive R&D pipeline consist of more than twenty novel tumor immunotherapy molecules based on monoclonal and bispecific antibody technology platforms.
2014
nanjing R&D center Established
80
%+
Proportion of R&D Personnel
20
+
R&D Pipeline
10
+
Issued Patents
)
